SAM #26-008476

NIH Sole Source Procurement: Thermo Fisher Scientific PCR System, Nucleic Acid Extractor, and Spectrophotometer

NIH Clinical Center, Department of Transfusion Medicine, Infectious Diseases Section, is announcing a sole source procurement to Fisher Scientific Company LLC for critical laboratory equipment. - Sole source, firm fixed price purchase order to Fisher Scientific Company LLC - Three Thermo Fisher Scientific branded systems required: - Real-Time PCR System - Automated Nucleic Acid Extractor - Microvolume Spectrophotometer - Equipment supports clinical research and diagnostic assay development for hepatitis viruses and transfusion-transmitted pathogens - Thermo Fisher Scientific systems uniquely meet NIH's requirements for accuracy, sensitivity, workflow integration, and cost efficiency - Procurement under FAR Part 13 Simplified Acquisition Procedures; exempt from competition - Interested parties may submit capabilities, but Fisher Scientific is the intended sole source vendor

Description

The NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section requires acquisition of a 1) Real-Time PCR System, 2) an Automated Nucleic Acid Extractor and 3) a microvolume spectrophotometer to support clinical research and the development, optimization, and validation of diagnostic assays for hepatitis viruses and other transfusion-transmitted pathogens.

•             Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies

•             NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing

•             Place of Performance: Bethesda, MD 20892 USA

POTS: 26-008476

Description:

This is a notice of intent, not a request for a quotation.  A solicitation document will not be issued and quotations will not be requested.

The National Institutes of Health (NIH) intends to award a fixed price purchase order to Fisher Scientific Company LLC, located at 300 Industry Dr, Pittsburgh, PA 15275, on a firm fixed price sole source award basis to provide the requirements to the National Institutes of Health.

The Thermo Fisher Scientific systems are uniquely qualified to meet the NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section’s requirements for detecting blood borne pathogens nucleic acid sequences using a fluorescence-based PCR in human-derived specimens to support assay development, optimization, and clinical research. No other commercially available system provides the same combination of performance, workflow integration, and cost efficiency accurate, sensitive, and quantitative detection of nucleic acid targets in human-derived specimens.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by September 2nd, 2026 at 10am EST.

View original listing